ProMIS Neurosciences, Inc.

233 articles about ProMIS Neurosciences, Inc.

• ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

  4/9/2024

  ProMIS Neurosciences Inc. today announced the publication of supportive preclinical data in the Journal of Biological Chemistry in an article titled, “Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1."

• ProMIS Neurosciences to Present in Upcoming Investor Conferences in April 2024

  4/4/2024

  ProMIS Neurosciences Inc., a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, announced that company management will participate in three upcoming investor conferences.

• ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

  4/1/2024

  ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update.

• ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

  3/11/2024

  ProMIS Neurosciences, Inc. announced that the European Patent Office, Japanese Patent Office and IP Australia, the Australian patent office, have recently allowed composition of matter and method of use patent applications related to ProMIS Neurosciences’ lead product candidate, PMN310, for the treatment of Alzheimer’s disease .

• ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

  2/22/2024

  ProMIS Neurosciences Inc. today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.

• ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

  1/22/2024

  ProMIS Neurosciences Inc. today announced the selection of a lead vaccine candidate, PMN400, against multiple synucleinopathies including Multiple System Atrophy (MSA), Parkinson’s disease and Lewy Body Dementia.

• ProMIS Neurosciences, Inc. Announces Leadership Transition

  1/3/2024

  ProMIS Neurosciences Inc., a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced a strategic leadership change.

• ProMIS Neurosciences Announces Publication on Novel Target for ALS

  12/20/2023

  ProMIS Neurosciences Inc. today announced a publication identifying Receptor for Activated C-Kinase 1 (RACK1) as a novel misfolded protein target for ALS and frontotemporal lobar degeneration (FTLD).

• ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease

  11/20/2023

  ProMIS Neurosciences Inc. today announced that the Company dosed the first subjects in a first-in-human Phase 1a clinical trial of PMN310 as a potential treatment for Alzheimer’s disease (AD).

• ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

  11/14/2023

  ProMIS Neurosciences Inc. (Nasdaq: PMN) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

• ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  9/6/2023

  ProMIS Neurosciences Inc. (Nasdaq: PMN) today announced that Gail Farfel, Ph.D., Chief Executive Officer and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 4:30 p.m. ET in New York, NY.

• ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

  8/21/2023

  ProMIS Neurosciences Inc. announced that it has entered into a securities purchase agreement with certain new and existing accredited investors to issue and sell an aggregate of approximately $20.4 million of common share units, each consisting of one of the Company’s common shares and one warrant to purchase one Common Share and pre-funded units, each consisting of one pre-funded warrant to purchase one Common Share and one Warrant.

• ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

  8/14/2023

  ProMIS Neurosciences Inc. (Nasdaq: PMN) today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

• ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline

  7/17/2023

  ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN) presented preclinical data further supporting the potential therapeutic advantage of lead candidate for AD, PMN310, a humanized IgG1 antibody directed toward toxic amyloid-beta oligomers (AβO).

• ProMIS Announces Completion of Continuance

  7/14/2023

  ProMIS Neurosciences Inc. is pleased to announce that it has completed its continuance (the “ Continuance ”) from the Canada Business Corporations Act into the Province of Ontario under the Business Corporations Act (Ontario) as of July 13, 2023.

• ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

  7/10/2023

  ProMIS Neurosciences Inc. today announced that it intends to consolidate trading of its shares on the Nasdaq exchange and as such has applied and received approval for a voluntary delisting of its common shares from the Toronto Stock Exchange ("TSX").

• ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

  6/30/2023

  ProMIS Neurosciences Inc. is pleased to announce the Annual Meeting of Shareholders was held by virtual web-cast meeting, on Thursday, June 29, 2023 at 9:30 a.m.

• CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

  6/29/2023

  ProMIS Neurosciences Inc. is issuing this release to correct the URL required to virtually access the Corporation’s Annual Meeting of Shareholders included in the Corporation’s Definitive Proxy Statement filed with the SEC and on SEDAR on June 1, 2023.

• ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

  5/15/2023

  ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN) today announced its first quarter 2023 financial results and recent highlights.

• ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease

  5/8/2023

  ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMN310 for the treatment of AD.